EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Perioperative Factor Xa Inhibitor Discontinuation for Patients Undergoing Procedures With Minimal or Low Bleeding Risk

So-Ryoung Lee, Kyung-Yeon Lee, Jong-Sung Park, Young Soo Lee, Yong Seog Oh, Sang-Jin Han, June Namgung, Ji Hyun Lee, Woo-Hyun Lim, Min Soo Ahn, Soonil Kwon, Hyo-Jeong Ahn und 4 weitere

JAMA Network Open · 07.02.2025 · 8 (2) · e2458742

DOI: 10.1001/jamanetworkopen.2024.58742 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JAMA Network Open, online erschienen am 07.02.2025. Verfasst von So-Ryoung Lee und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Factor Xa Inhibitors, Atrial Fibrillation, Thromboembolism, Hemorrhage. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Discontinuation of oral anticoagulant treatment is common in clinical practice due to concerns about bleeding, even for procedures with minimal to low bleeding risk.

Objective

To explore whether perioperative discontinuation of factor Xa inhibitors is associated with major bleeding and thromboembolic events in patients with atrial fibrillation (AF) undergoing procedures with minimal to low bleeding risk. Design, Setting, and Participants This prospective, multicenter, single-arm cohort study conducted in Korea included patients with AF who planned to undergo a procedure with minimal to low bleeding risk between September 25, 2020, and April 5, 2024. Exposure The PERIXa (Perioperative Factor Xa Inhibitor Discontinuation in Patients With Atrial Fibrillation Undergoing Minimal to Low Bleed Risk Procedures) protocol recommending giving the last dose of factor Xa inhibitor (ie, apixaban, edoxaban, or rivaroxaban) 24 hours before the procedure (ie, endoscopy, dental procedure, or ocular surgery) and restarting treatment with the inhibitor the next day. Main Outcomes and Measures The primary outcome was major bleeding, and the secondary outcome included a composite of thromboembolic events 30 days after the index procedure with minimal to low bleeding risk.

Results

In total, 1902 patients were included in the modified intention-to-treat analysis set encompassing all patients who underwent the intended procedure (mean [SD] age, 70.4 [8.8] years; 1135 [59.7%] male; mean [SD] CHA 2 DS 2 -VASc [congestive heart failure, hypertension, age 75 years or older, diabetes, stroke, vascular disease, age 65-74 years, and female sex; range, 0-9, with higher scores indicating higher risk of stroke] score, 2.8 [1.3]; mean [SD] HAS-BLED [hypertension, kidney or liver disease, stroke history, prior bleeding, unstable international normalized ratio, age >65 years, and drug or alcohol use; range, 0-9, with higher scores indicating higher risk of bleeding] score, 1.6 [0.7]). Among them, 921 (48.4%) were receiving apixaban, 616 (32.4%) were receiving edoxaban, and 365 (19.2%) were receiving rivaroxaban. Of the total procedures, 948 (49.8%) were endoscopy, 820 (43.1%) were dental procedures, and 120 (6.3%) were ocular surgery. The 30-day event rate of major bleeding was 0.1% (n = 2), and there were no composite thromboembolic events. The results were consistent in the per-protocol analysis, and no differences were observed by procedure category or factor Xa inhibitor type. Conclusions and Relevance In this cohort study, patients with AF receiving a factor Xa inhibitor and undergoing a procedure with minimal to low bleeding risk had low rates of major bleeding and thromboembolism when following the standardized PERIXa protocol for perioperative management of oral anticoagulant treatment, suggesting that this may be a safe and reasonable option for this patient population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Factor Xa InhibitorsAtrial FibrillationThromboembolismHemorrhagePerioperative CareHumansMaleFemaleAgedProspective StudiesMiddle AgedRepublic of KoreaRivaroxabanAged, 80 and overPyridonesPyrazolesAnticoagulantsPyridinesThiazoles

Substanzen

Factor Xa InhibitorsedoxabanapixabanRivaroxabanPyridonesPyrazolesAnticoagulantsPyridinesThiazoles

Autor:innen und Institutionen

  • Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
  • Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Department of Cardiology, Dong-A University Hospital, Busan, Republic of Korea.
  • Department of Cardiology, Daegu Catholic University Medical Center, Daegu, Republic of Korea.
  • Department of Cardiology, The Catholic University of Korea, St Mary's Hospital, Seoul, Republic of Korea.
  • Department of Internal Medicine, College of Medicine, Hallym University, Anyang, Republic of Korea.

Zitieren

APA

Lee, S. R., Lee, K. Y., Park, J. S., Lee, Y. S., Oh, Y. S., Han, S. J., Namgung, J., Lee, J. H., Lim, W. H., Ahn, M. S., Kwon, S., Ahn, H. J., Oh, S., Lip, G. Y. H., Choi, E. K., & PERIXa Investigators (2025). Perioperative Factor Xa Inhibitor Discontinuation for Patients Undergoing Procedures With Minimal or Low Bleeding Risk. JAMA Network Open, 8(2), e2458742. https://doi.org/10.1001/jamanetworkopen.2024.58742

Vancouver

Lee SR, Lee KY, Park JS, Lee YS, Oh YS, Han SJ, et al. Perioperative Factor Xa Inhibitor Discontinuation for Patients Undergoing Procedures With Minimal or Low Bleeding Risk. JAMA Network Open. 2025;8(2):e2458742. doi:10.1001/jamanetworkopen.2024.58742

BibTeX
@article{Lee2025,
  author = {Lee, So-Ryoung and Lee, Kyung-Yeon and Park, Jong-Sung and Lee, Young Soo and Oh, Yong Seog and Han, Sang-Jin and Namgung, June and Lee, Ji Hyun and Lim, Woo-Hyun and Ahn, Min Soo and Kwon, Soonil and Ahn, Hyo-Jeong and Oh, Seil and Lip, Gregory Y H and Choi, Eue-Keun and PERIXa Investigators, PERIXa Investigators},
  title = {Perioperative Factor Xa Inhibitor Discontinuation for Patients Undergoing Procedures With Minimal or Low Bleeding Risk},
  journal = {JAMA Network Open},
  year = {2025},
  volume = {8},
  number = {2},
  pages = {e2458742},
  doi = {10.1001/jamanetworkopen.2024.58742}
}
Kostenlos starten →